Core Insights - Guardian Pharmacy Services, Inc. reported a strong performance for the full year 2025, with organic revenue growth of 13% and total reported revenue growth of 18% driven by acquisitions and operational efficiencies [1][6][17] - The company achieved adjusted EBITDA growth of 27% year over year, with margins expanding to 7.9% [6][20] - The company is focused on maintaining growth momentum into 2026, raising adjusted EBITDA guidance to $120 million to $124 million while keeping revenue forecasts stable at $1.4 billion to $1.42 billion [14][23] Financial Performance - For Q4 2025, Guardian Pharmacy Services served over 205,000 residents, a 10% increase year over year, with script volume growing 14% and revenue increasing 17% to $397.6 million [17] - Gross profit rose 27% to $85.5 million, with gross margins expanding to 21.5% from 19.8% a year ago [17][20] - Adjusted EBITDA for the full year reached $115 million, exceeding previous guidance [22] Operational Highlights - The company completed three acquisitions midyear, contributing to revenue growth and operational scale [6][21] - Over 100,000 clinical interventions were performed by pharmacists, benefiting approximately 74,000 residents, and the proactive insurance optimization program resulted in $56 million in cost savings [8] - Vaccine clinics administered over 120,000 vaccines, leading to a 9% increase in script volumes for the full vaccine season [8] Strategic Outlook - The company is navigating changes from the Inflation Reduction Act (IRA), which has introduced new pricing and reimbursement dynamics [10][11] - The demographic shift with the aging population is expected to create additional demand for long-term care pharmacy services [12] - The company is actively monitoring industry developments, including potential opportunities arising from competitors facing financial difficulties [13][46] Investment and Growth Strategy - Guardian Pharmacy Services continues to invest in acquisitions and greenfield startups while enhancing data analytics capabilities [7][21] - The company increased its cash balance by approximately $60 million, reflecting strong cash generation [7][20] - Future growth is supported by a disciplined approach to capital allocation and operational efficiencies [6][15]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth of 12% [19] - Adjusted EBITDA grew 53% year-over-year to $39.5 million, with margins expanding to 9.9% [22] - Full-year 2025 adjusted EBITDA was $115 million, exceeding previous guidance [25] - The company increased its cash balance to $66 million, up from $36 million in Q3 2025 [22] Business Line Data and Key Metrics Changes - The company served over 205,000 residents, a 10% increase year-over-year [19] - Script volume grew 14% year-over-year, with vaccine script volumes up 3% [19][20] - Gross profit rose 27% to $85.5 million, with gross margins expanding to 21.5% from 19.8% [19] Market Data and Key Metrics Changes - The company anticipates a revenue forecast of $1.4 billion to $1.42 billion for 2026, reflecting new pricing impacts from the IRA [26] - The long-term care pharmacy environment is evolving with ongoing consolidation and increasing operational complexity [13] Company Strategy and Development Direction - The company plans to continue investing in acquisitions and greenfield startups while enhancing data analytics capabilities [8] - The company aims to offset anticipated EBITDA impacts from the IRA and maintain service levels during industry transitions [12][11] - The focus remains on supporting partners with reliable execution amid industry changes [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth momentum despite industry challenges, raising 2026 adjusted EBITDA guidance to $120 million-$124 million [17][26] - The demographic shift with the aging population is expected to create incremental tailwinds for the company [13] - Management is closely monitoring the operational complexities introduced by the IRA [11] Other Important Information - The company completed three acquisitions mid-year, contributing to reported revenue growth of 18% for the full year [6] - The company achieved a full-year return on equity of 27% [8] Q&A Session Summary Question: Can you help us understand the durable aspects of Q4 results? - Management indicated that the run rate for EBITDA is approximately $110 million, with variability in Q4 not projected to continue [32] Question: Did the vaccine program contribute more this year than last year? - Management confirmed that the vaccine program continued to be significant in Q4, with improved profitability [34] Question: What progress has been made in balancing profit contributions between generics and branded drugs? - Management noted progress in aligning gross margin dollars with the high volume of generic prescriptions [36] Question: Is the gap between potential margin and realized margin still the same? - Management indicated that the gap has increased to approximately 90 basis points [37] Question: Can you discuss opportunities arising from competitors facing challenges? - Management acknowledged potential opportunities from competitors in distress, particularly in the context of ongoing bankruptcy processes [48] Question: Are you seeing efficiencies in labor costs? - Management stated that efficiencies are primarily due to scaling the existing platform rather than improvements in labor inflation [49] Question: How is the integration of recently acquired facilities progressing? - Management reported faster ramp-up and integration of recently acquired facilities, particularly in the Pacific Northwest [56] Question: What is the outlook for M&A opportunities given the current market conditions? - Management expressed a robust pipeline for M&A in 2026, while remaining disciplined in their approach [60]

Investment Rating - The industry view is rated as In-Line [7] Core Insights - The demand for data centers remains strong across multiple utility companies, with significant capital expenditure (capex) opportunities identified [2][3] - Regulatory environments in states like Missouri and Texas are improving, which is expected to support utility growth and infrastructure investments [2][3] - Long-term earnings per share (EPS) growth outlook for New Jersey Resources (NJR) is projected at 7-9%, supported by residential growth and active pipeline replacement programs [4] Summary by Company Ameren (AEE) - Active conversations with data centers and a recent tariff proposal filed in Missouri to ensure regulatory comfort for large loads [2] - Equity needs are met through 2026, with manageable capital requirements following recent storms [2] CenterPoint Energy (CNP) - Continued strong demand for data centers and multiple capex opportunities, including significant projects in Texas [3] - Anticipated guidance refresh in September to reflect new capex opportunities [3] New Jersey Resources (NJR) - Confident in achieving 7-9% long-term EPS growth, with a quiet regulatory agenda expected after recent rate case conclusions [4] - Focus on utility-like earnings in unregulated businesses through stable pricing and long-term contracts [4] Other Companies - Duke Energy (DUK) has high confidence in its data center pipeline and is streamlining interconnection processes [10] - PPL Corp (PPL) is constructive on the regulatory backdrop in Kentucky and has not seen a slowdown in its data center pipeline [12] - Xcel Energy (XEL) has safe harbored renewables in its plans and is on track to achieve data center load growth [14] - Spire (SR) anticipates a potential settlement in its Missouri rate case, which could improve its earnings outlook [21][22]